Evidence map›Paper›PMID 26157579›Full record

ArticleBoneKEy reports2015

TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Keith R Stayrook, Justin K Mack, Donna Cerabona, Daniel F Edwards, Hai H Bui, Maria Niewolna, Pierrick Gj Fournier, Khalid S Mohammad, David L Waning, Theresa A Guise

Abstract read
In one paragraph

Article in BoneKEy reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Keith R StayrookDepartment of Pharmacology, Indiana University School of Medicine , Indianapolis, IN, USA ; Lilly Research Laboratories, Eli Lilly & Company , Indianapolis, IN, USA.
Justin K MackLilly Research Laboratories, Eli Lilly & Company , Indianapolis, IN, USA.
Donna CerabonaDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine , Indianapolis, IN, USA.
Daniel F EdwardsLilly Research Laboratories, Eli Lilly & Company , Indianapolis, IN, USA.
Hai H BuiLilly Research Laboratories, Eli Lilly & Company , Indianapolis, IN, USA.
Maria NiewolnaDivision of Endocrinology and Metabolism, Department of Medicine, Indiana University-Purdue University at Indianapolis , Indianapolis, IN, USA.
Pierrick Gj FournierDivision of Endocrinology and Metabolism, Department of Medicine, Indiana University-Purdue University at Indianapolis , Indianapolis, IN, USA.
Khalid S MohammadDivision of Endocrinology and Metabolism, Department of Medicine, Indiana University-Purdue University at Indianapolis , Indianapolis, IN, USA.
David L WaningDivision of Endocrinology and Metabolism, Department of Medicine, Indiana University-Purdue University at Indianapolis , Indianapolis, IN, USA.
Theresa A GuiseDepartment of Pharmacology, Indiana University School of Medicine , Indianapolis, IN, USA ; Division of Endocrinology and Metabolism, Department of Medicine, Indiana University-Purdue University at Indianapolis , Indianapolis, IN, USA.
Indiana University – Purdue University Indianapolis · US

Funding

TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASISR01CA069158 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GUISE, THERESA A · 2001 to 2012
$2.8M
Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor GrowthU01CA143057 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI BHOWMICK, NEIL A., GUISE, THERESA A · 2011 to 2015
$2.7M
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle.R21CA205437 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI WANING, DAVID L · 2016 to 2017
$372k
BREAST CANCER METASTASES TO BONE--ROLE OF PTHRP &TGFBR29CA069158 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI GUISE, THERESA A · 1996 to 2000
$102k
NCI NIH HHS R01 CA069158NCI NIH HHS R29 CA069158NCI NIH HHS U01 CA143057
6 · The paper itself

Abstract

Mechanistic understanding of the preferential homing of circulating tumor cells to bone and their perturbation on bone metabolism within the tumor-bone microenvironment remains poorly understood. Alteration in both transforming growth factor β (TGFβ) signaling and sphingolipid metabolism results in the promotion of tumor growth and metastasis. Previous studies using MDA-MB-231 human breast cancer-derived cell lines of variable metastatic potential were queried for changes in sphingolipid metabolism genes to explore correlations between TGFβ dependence and bone metastatic behavior. Of these genes, only sphingosine kinase-1 (SPHK1) was identified to be significantly increased following TGFβ treatment. Induction of SPHK1 expression correlated to the degree of metastatic capacity in these MDA-MB-231-derived cell lines. We demonstrate that TGFβ mediates the regulation of SPHK1 gene expression, protein kinase activity and is critical to MDA-MB-231 cell viability. Furthermore, a bioinformatic analysis of human breast cancer gene expression supports SPHK1 as a hallmark TGFβ target gene that also bears the genetic fingerprint of the basal-like/triple-negative breast cancer molecular subtype. These data suggest a potential new signaling axis between TGFβ/SphK1 that may have a role in the development, prognosis or the clinical phenotype associated with tumor-bone metastasis.

Identifiers

PMID26157579
PMCPMC4495778
OpenAlexW2337722192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.